Recombinant Human CD8 alpha Protein (Site‑Specific PE Conjugation, His Tag)｜Cat:10980‑H86C‑SPRecombinant Human CD8 alpha Protein (Site‑Specific PE Conjugation, His Tag)
Cat No: 10980‑H86C‑SP｜Official product page: https://cn.sinobiological.com/recombinant-proteins/human-cd8-alpha-10980-h86c-sp
Specifications
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
Protein Construction
A DNA sequence encoding the Human CD8A (NP_001759.3) (Met 1‑Asp 182) was expressed with a C‑terminal polyhistidine tag. The protein is site‑specifically conjugated with PE (Excitation= 495 ‑ 566 nm, Emission Max.= 575 nm).
Alternate Names
CD8 CD8alpha IMD116 Leu2 MAL p32
Background
T‑cell surface glycoprotein CD8 alpha chain, also known as CD8a, is a single‑pass type I membrane protein. The CD8 glycoprotein is expressed by thymocytes, mature T cells and natural killer (NK) cells and has been implicated in the recognition of monomorphic determinants on major histocompatibility complex (MHC) Class I antigens, and in signal transduction during the course of T‑cell activation. Both human and rodent CD8 antigens are comprised of two distinct polypeptide chains, alpha and beta. The Ig domains of CD8 alpha are involved in controlling the ability of CD8 to be expressed. Mutation of B‑ and F‑strand cysteine residues in CD8 alpha reduced the ability of the protein to fold properly and, therefore, to be expressed. Defects in CD8A are a cause of familial CD8 deficiency. Familial CD8 deficiency is a novel autosomal recessive immunologic defect characterized by absence of CD8+ cells, leading to recurrent bacterial infections.
Documents available on official page: Datasheet, COA, MSDS, Protocol, Reference citations.
关键字： 定点标记;CD8A蛋白;CD8A重组蛋白;重组CD8A蛋白;人CD8A蛋白;
北京义翘神州科技股份有限公司作为国家高新技术企业，主要从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务，同时也为制药公司或者生物技术公司提供单克隆抗体候选药物的临床前规模生产服务。义翘神州拥有多项先进的核心技术以及从研发生产到放大生产的技术平台，为重组蛋白或者抗体试剂的高通量、高效率研发生产提供保障，旨在为全球制药企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。
北京义翘神州是入选科技部"现代服务创新发展示范企业"的唯一的一家生物技术企业，是北京市民营企业科技创新百强，获批北京市单克隆抗体技术重点实验室，多次承担国家科技部重大新药创制专项、863科技攻关项目和北京市科委项目。